MANTLE CELL LYMPHOMA REFRACTORY

This adverse event was reported 66 times

These drugs are most commonly taken by patients reporting MANTLE CELL LYMPHOMA REFRACTORY:

# Drug Count
0 RITUXIMAB 32
1 IBRUTINIB 23
2 VENETOCLAX 16
3 CYCLOPHOSPHAMIDE 15
4 CYCLOPHOSPHAMIDE FOR INJECTION 15
5 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 15
6 OBINUTUZUMAB 13
7 DOXORUBICIN 12
8 PREDNISOLONE 12
9 PREDNISOLONE ORAL 12
See all common drugs associated with MANTLE CELL LYMPHOMA REFRACTORY

MANTLE CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BREXUCABTAGENE AUTOLEUCEL 6 0.0028
1 PIRTOBRUTINIB 1 0.0010
2 TERBINAFINE TABLETS 250 MG 1 0.0008
3 OBINUTUZUMAB 13 0.0008
4 ZANUBRUTINIB 2 0.0004
5 RASBURICASE 1 0.0004
6 BENDAMUSTINE HYDROCHLORIDE 3 0.0004
7 BENDAMUSTINE HCL 5 0.0003
8 IBRUTINIB 23 0.0003
9 VENETOCLAX 16 0.0003
See all drugs enriched for association with MANTLE CELL LYMPHOMA REFRACTORY

MANTLE CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 BCL-2 Inhibitor [EPC] 16 0.0003
1 CD20-directed Cytolytic Antibody [EPC] 36 0.0001
2 Antifibrinolytic Agent [EPC] 1 0.0001
3 Stimulant Laxative [EPC] 1 0.0001
4 Vasopressin V2 Receptor Antagonist [EPC] 1 0.0001
5 Alkylating Drug [EPC] 16 0.0001
6 Xanthine Oxidase Inhibitor [EPC] 11 0.0001
7 Proteasome Inhibitor [EPC] 6 0.0001
8 Kinase Inhibitor [EPC] 25 0.0000
9 Topoisomerase Inhibitor [EPC] 3 0.0000
See all drug classes enriched for association with MANTLE CELL LYMPHOMA REFRACTORY